# Rapport Therapeutics, Inc.: overview

RAPP · Nasdaq · CIK 2012593 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/rapp.md) · [Financials](/companies/rapp/financials.md) · [Filings](/companies/rapp/filings.md) · [Insiders](/companies/rapp/insiders.md)

Latest reported revenue: [$0](/filings/0001193125-26-333862.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 5, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-333862).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | [0.0](/filings/0001193125-26-210355.md) | [0.0](/filings/0001193125-26-333862.md) | not reported | not reported | [20.0](/filings/0001193125-26-210355.md) | [0.0](/filings/0001193125-26-333862.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | [(121.1%)](/filings/0001193125-26-210355.md) | not reported |
| Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | [(99.3%)](/filings/0001193125-26-333862.md) | not reported |
| Diluted EPS | $ per share | [(0.50)](/filings/0001193125-25-268096.md) | not reported | [(0.68)](/filings/0001193125-26-210355.md) | [(0.75)](/filings/0001193125-26-333862.md) | [(0.71)](/filings/0001193125-25-268096.md) | not reported | [(0.42)](/filings/0001193125-26-210355.md) | [(1.19)](/filings/0001193125-26-333862.md) |
| Free cash flow | $m | [(16.6) d](/filings/0001193125-25-268096.md) | [(14.7) d](/filings/0001193125-26-099360.md) | [(20.5)](/filings/0001193125-26-210355.md) | [(25.1) d](/filings/0001193125-26-333862.md) | [(17.6) d](/filings/0001193125-25-268096.md) | [(24.9) d](/filings/0001193125-26-099360.md) | [(13.1)](/filings/0001193125-26-210355.md) | [(41.5) d](/filings/0001193125-26-333862.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported |
| Gross margin | % | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported |
| Net margin | % | not reported | not reported | not reported |
| Diluted EPS | $ per share | [(23.10)](/filings/0000950170-25-036828.md) | [(3.78)](/filings/0001193125-26-099360.md) | [(2.86)](/filings/0001193125-26-099360.md) |
| Free cash flow | $m | [(28.8)](/filings/0000950170-25-036828.md) | [(67.2)](/filings/0001193125-26-099360.md) | [(88.1)](/filings/0001193125-26-099360.md) |

- Revenue. XBRL not reported.
- Gross margin (gross profit / revenue). XBRL not reported.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/rapp/insiders.md)

| Date | Insider | Role | Transaction | Shares | Reported price | Value | Filing |
| --- | --- | --- | --- | ---: | ---: | ---: | --- |
| 2026-10-23 | [Sanchez Ramiro](/insiders/1830326.md) | Director | Purchase (P) | 3,600 | $27.3549 | $98.5k | [Form 4](/filings/0001193125-26-430397.md) |
| 2026-10-22 | [Paul Steven M](/insiders/1237564.md) | Director | Purchase (P) | 35,714 | $27.28 | $974.3k | [Form 4](/filings/0001193125-26-429073.md) |
| 2026-10-22 | [Young Wendy B.](/insiders/2042847.md) | Director | Purchase (P) | 3,789 | $26.39 | $100.0k | [Form 4](/filings/0001193125-26-429074.md) |
| 2026-10-22 | [Silva Paul M](/insiders/1446372.md) | Director | Purchase (P) | 3,680 | $27.075 | $99.6k | [Form 4](/filings/0001193125-26-429075.md) |
| 2026-10-22 | [Maraganore John](/insiders/1180432.md) | Director | Purchase (P) | 1,172 | $26.9173 | $31.5k | [Form 4](/filings/0001193125-26-429071.md) |
| 2026-10-22 | [Maraganore John](/insiders/1180432.md) | Director | Purchase (P) | 8,239 | $26.3799 | $217.3k | [Form 4](/filings/0001193125-26-429071.md) |
| 2026-10-21 | [Ceesay Abraham](/insiders/1722140.md) | Chief Executive Officer, Director, Officer | Sale (S) | 2,210 | $29.1618 | $64.4k | [Form 4](/filings/0001193125-26-430504.md) |

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $298.9m | 7,172,894 |  | Added +3,955 |
| [TRV GP V, LLC](/funds/1990717.md) | 2026-06-30 | $261.7m | 6,280,525 |  | Reduced −854,708 |
| [ARCH Venture Management, LLC](/funds/1274403.md) | 2026-06-30 | $155.4m | 3,728,738 |  | Unchanged |
| [Capital International Investors](/funds/1562230.md) | 2026-06-30 | $121.8m | 2,921,958 |  | Reduced −176,015 |
| [GOLDMAN SACHS GROUP INC](/funds/886982.md) | 2026-06-30 | $121.3m | 2,910,449 |  | Reduced −31,802 |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $112.5m | 2,699,786 |  | Added +193,831 |
| [Cormorant Asset Management, LP](/funds/1583977.md) | 2026-06-30 | $110.7m | 2,657,521 |  | Reduced −300,000 |
| [Sofinnova Investments, Inc.](/funds/1631134.md) | 2026-06-30 | $79.4m | 1,904,408 |  | Unchanged |
| [JOHNSON & JOHNSON](/funds/200406.md) | 2026-06-30 | $74.4m | 1,784,517 |  | Unchanged |
| [Polar Capital Holdings Plc](/funds/1837309.md) | 2026-06-30 | $67.0m | 1,608,514 |  | Reduced −33,947 |

## Recent filings

[All 243 filings](/companies/rapp/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-20 | 06:05 ET | [8-K](/filings/0001193125-26-425647.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-425647 |
| 2026-08-05 | 07:30 ET | [10-Q](/filings/0001193125-26-333862.md) | Quarterly report, period 2026-06-30 | 0001193125-26-333862 |
| 2026-08-05 | 07:17 ET | [8-K](/filings/0001193125-26-333853.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-333853 |
| 2026-06-10 | 16:12 ET | [8-K](/filings/0001193125-26-265841.md) | 5.07 Shareholder vote results | 0001193125-26-265841 |
| 2026-05-07 | 07:30 ET | [10-Q](/filings/0001193125-26-210355.md) | Quarterly report, period 2026-03-31 | 0001193125-26-210355 |
| 2026-05-07 | 07:15 ET | [8-K](/filings/0001193125-26-210324.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-210324 |
| 2026-04-23 | 07:20 ET | [DEF 14A](/filings/0001193125-26-171828.md) | Proxy statement, period 2026-06-10 | 0001193125-26-171828 |
| 2026-04-21 | 16:50 ET | [8-K](/filings/0001193125-26-167078.md) | 7.01 Regulation FD disclosure; 8.01 Other events | 0001193125-26-167078 |
| 2026-03-10 | 07:25 ET | [10-K](/filings/0001193125-26-099360.md) | Annual report, period 2025-12-31 | 0001193125-26-099360 |
| 2026-03-10 | 07:11 ET | [8-K](/filings/0001193125-26-099336.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-099336 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-099360.md), filed Mar 10, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/0b3fb66e-0e6c-4695-949c-897ebee49c8d)

## About the filer

- CIK: 2012593
- Tickers: RAPP
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: <br>Emerging growth company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 07:08 ET. No prices; not investment advice.